For instance, the upregulation of P-gp in tumor cells by the PD-1/PD-L1 axis [95] can contribute to resistance against chemotherapeutic agents often used in combination with immune checkpoint inhibitors (ICIs) like anti-PD-1 or anti-PD-L1 antibodies [96]. The gene discussed is PGP; the disease is neoplasm.